trending Market Intelligence /marketintelligence/en/news-insights/trending/y4T0izhVUv0UOuMni1Ozew2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bionomics to sell 2 French subsidiaries to Domain Therapeutics

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Bionomics to sell 2 French subsidiaries to Domain Therapeutics

Thebarton, Australia-based Bionomics Ltd. agreed to sell its two French subsidiaries to Domain Therapeutics SA for about €1.8 million.

The units being sold in the transaction are Neurofit SAS and PC SAS, which operate as contract research organizations in France.

Bionomics said the purchase price is equivalent to the intercompany debt it owed to Neurofit and PC for the scientific research services conducted on its drug candidates. Following the transaction, Illkirch-Strasbourg, France-based Domain Therapeutics will assume the debt.

The acquisition offer is subject to conditions, including the signing of definitive contractual documentation and regulatory approval.

Completion of the deal is expected to occur Jan. 31, 2020.